Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 11/2010

01.11.2010 | Brief Report

Serotypes and susceptibilities of paediatric clinical isolates of Streptococcus pneumoniae in Crete, Greece, before and after the heptavalent pneumococcal conjugate vaccine

verfasst von: S. Maraki, G. Samonis, E. Galanakis

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

All Streptococcus pneumoniae strains isolated from paediatric clinical samples at Heraklion University General Hospital in the 10-year period 2000–2009 were tested for serotype and susceptibility to antimicrobials. Among a total of 258 strains, 159 were isolated in the 5-year period 2000–2004, before the introduction of the heptavalent pneumococcal conjugate vaccine (PCV7), and 99 in the post-PCV7 5-year period 2005–2009. The prevalence of PCV7-included serotypes decreased in the post-PCV7 period (p = 0.0002), but an increase was observed for serotypes 7F (p = 0.002) and 19A (p = 0.004). Pan-susceptibility rates and susceptibility to cotrimoxazole increased in the post-PCV7 period (p = 0.01 and p = 0.008, respectively), but serotype 19A emerged as a contributor to multi-resistance (p = 0.007). PCV7 was followed by decreased S. pneumoniae resistance and prevalence of vaccine-related serotypes but increased prevalence of serotypes 7F and 19A. Continuing surveillance is required after the recent introduction of PCV10 and PCV13.
Literatur
1.
Zurück zum Zitat Isaacman DJ, McIntosh ED, Reinert RR (2010) Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 14:e197–e209CrossRefPubMed Isaacman DJ, McIntosh ED, Reinert RR (2010) Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 14:e197–e209CrossRefPubMed
2.
Zurück zum Zitat Maraki S, Christidou A, Tselentis Y (2001) Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae isolates from Crete, Greece. Int J Antimicrob Agents 17:465–469CrossRefPubMed Maraki S, Christidou A, Tselentis Y (2001) Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae isolates from Crete, Greece. Int J Antimicrob Agents 17:465–469CrossRefPubMed
3.
Zurück zum Zitat Zissis NP, Syriopoulou V, Kafetzis D, Daikos GL, Tsilimingaki A, Galanakis E, Tsangaropoulou I (2004) Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive infections and acute otitis media in children. Eur J Pediatr 163:364–368CrossRefPubMed Zissis NP, Syriopoulou V, Kafetzis D, Daikos GL, Tsilimingaki A, Galanakis E, Tsangaropoulou I (2004) Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive infections and acute otitis media in children. Eur J Pediatr 163:364–368CrossRefPubMed
4.
Zurück zum Zitat Paraskakis I, Kafetzis DA, Chrisakis A, Papavasilliou H, Kirikou H, Pangalis A, Tzouvelekis LS, Athanasiou T, Legakis NJ; National Surveillance Network for Pneumococcal Resistance (2006) Serotypes and antimicrobial susceptibilities of 1033 pneumococci isolated from children in Greece during 2001–2004. Clin Microbiol Infect 12:490–493CrossRefPubMed Paraskakis I, Kafetzis DA, Chrisakis A, Papavasilliou H, Kirikou H, Pangalis A, Tzouvelekis LS, Athanasiou T, Legakis NJ; National Surveillance Network for Pneumococcal Resistance (2006) Serotypes and antimicrobial susceptibilities of 1033 pneumococci isolated from children in Greece during 2001–2004. Clin Microbiol Infect 12:490–493CrossRefPubMed
5.
Zurück zum Zitat Grivea IN, Panagiotou M, Tsantouli AG, Syrogiannopoulos GA (2008) Impact of heptavalent pneumococcal conjugate vaccine on nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among day-care center attendees in central Greece. Pediatr Infect Dis J 27:519–525CrossRefPubMed Grivea IN, Panagiotou M, Tsantouli AG, Syrogiannopoulos GA (2008) Impact of heptavalent pneumococcal conjugate vaccine on nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among day-care center attendees in central Greece. Pediatr Infect Dis J 27:519–525CrossRefPubMed
6.
Zurück zum Zitat Grivea IN, Tsantouli AG, Chryssanthopoulou DC, Syrogiannopoulos GA (2010) Interaction of the heptavalent pneumococcal conjugate vaccine and the use of individual antibiotics among children on nasopharyngeal colonization with erythromycin-resistant Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 29:97–105CrossRefPubMed Grivea IN, Tsantouli AG, Chryssanthopoulou DC, Syrogiannopoulos GA (2010) Interaction of the heptavalent pneumococcal conjugate vaccine and the use of individual antibiotics among children on nasopharyngeal colonization with erythromycin-resistant Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 29:97–105CrossRefPubMed
7.
Zurück zum Zitat Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A (2006) Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case–control study. Lancet 368:1495–1502CrossRefPubMed Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A (2006) Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case–control study. Lancet 368:1495–1502CrossRefPubMed
8.
Zurück zum Zitat Fenoll A, Granizo JJ, Aguilar L, Giménez MJ, Aragoneses-Fenoll L, Hanquet G, Casal J, Tarragó D (2009) Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 47:1012–1020CrossRefPubMed Fenoll A, Granizo JJ, Aguilar L, Giménez MJ, Aragoneses-Fenoll L, Hanquet G, Casal J, Tarragó D (2009) Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 47:1012–1020CrossRefPubMed
Metadaten
Titel
Serotypes and susceptibilities of paediatric clinical isolates of Streptococcus pneumoniae in Crete, Greece, before and after the heptavalent pneumococcal conjugate vaccine
verfasst von
S. Maraki
G. Samonis
E. Galanakis
Publikationsdatum
01.11.2010
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 11/2010
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-010-1005-0

Weitere Artikel der Ausgabe 11/2010

European Journal of Clinical Microbiology & Infectious Diseases 11/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.